dpp-4 inhibitor and glp-1 receptor agonist combination not recommended ada GLP-1-RA inhibitors in the management of type 2 diabetes GLP-1 receptor agonists or DPP-4
Description
A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes
Aten Primaria (2017) 49:2949
Introduction What is GLP-1 and why it matters Dietary strategies to increase GLP-1 Lifestyle habits that support GLP-1 Supplements and nutraceuticals Conclusions References Further reading This article explains how specific foods, lifestyle habits, and nutraceuticals can modestly enhance endogenous GLP-1 activity to support appetite regulation and metabolic health
These results prove that GLP-1-based therapy may reduce inflammation and improve fatty liver disease in animal and human models
